Question explored with the scientific record
Can Warm aiha be caused by vaccination?
The short version: the evidence retrieved does not contain a single study that directly tests whether vaccination can trigger or worsen warm autoimmune hemolytic anemia (wAIHA). The gap itself is the finding.
The evidence you provided covers treatment sequencing [1], drug mechanisms [2], patient-reported fatigue [3], antibody repertoires [4], real-world rituximab use [5], a pregnancy case [6], epidemiology [7], plasma exchange [8], a rituximab trial [9], thrombosis risk [10], a hypereosinophilic syndrome case [11], RBC survival measurement [12], childhood IgM-mediated AIHA [13], a paraneoplastic case [14], and several unrelated vaccine immunogenicity studies [15-25]. None of these studies were designed to answer whether vaccination causes or triggers wAIHA. No study compared wAIHA incidence in vaccinated versus unvaccinated populations. No study followed a cohort prospectively for new-onset wAIHA after any vaccine. No study examined relapse rates in patients with existing wAIHA after vaccination.
The epidemiology paper [7] gives the background incidence of wAIHA at 0.8 to 3 cases per 100,000 person-years. That number is the baseline. Without a vaccinated-versus-unvaccinated comparison, you cannot know whether vaccination raises, lowers, or leaves that rate unchanged. The absence of this comparison in the published literature is not evidence of safety. It is evidence that the question was never studied with a design capable of answering it.
My call: the evidence retrieved does not answer whether vaccination can cause or trigger wAIHA. The most informative study design was never run. Confidence: not clear, because the question was not tested.
Sources examined 25
-
Second-Line Therapy Sequencing in Primary Warm Autoimmune Hemolytic Anemia: Splenectomy-Rituximab Versus Rituximab-Splenectomy
A Markov-model health-economic analysis compares second-line sequencing options for adult primary warm autoimmune hemolytic anemia, finding splenectomy-then-rituximab and rituximab-then-splenectomy yield similar lifetime costs and QALYs with no clear advantage under current vacc…
DOI: 10.1182/blood-2023-189957 -
FcRn Blockade as a Targeted Therapeutic Strategy in Antibody-Mediated Autoimmune Diseases: A Focus on Warm Autoimmune Hemolytic Anemia
A comprehensive review of FcRn blockade as a targeted therapeutic strategy for IgG-driven autoimmune diseases, focusing on warm autoimmune hemolytic anemia (wAIHA) and the clinical development of Nipocalimab and other FcRn inhibitors, their mechanisms, trial results, safety, and…
DOI: 10.3390/antib14030065 -
Content validity and meaningful change for the FACIT-Fatigue scale in warm autoimmune hemolytic anemia: results from qualitative interview studies with patients
This study investigates the content validity of the FACIT-Fatigue scale in patients with warm autoimmune hemolytic anemia (wAIHA) through qualitative interviews, revealing that fatigue is the primary symptom affecting patients' quality of life and that the FACIT-Fatigue is relev…
DOI: 10.1186/s41687-025-00930-0 -
Altered antibody repertoires of plasma IgM and IgG toward nonself antigens in patients with warm autoimmune hemolytic anemia
The study shows that patients with warm autoimmune hemolytic anemia (WAIHA) have broadly altered plasma antibody repertoires toward nonself antigens, characterized by markedly reduced IgM reactivity and distinct IgG patterns compared with healthy controls, with immunosuppressive…
DOI: 10.1016/s0198-8859(01)00225-7 -
Treatment patterns and outcomes among warm autoimmune hemolytic anemia patients receiving rituximab in the United States: A retrospective database study
Real-world US data show rituximab was used in about 29% of warm autoimmune hemolytic anemia patients, most receiving a single cycle, with relapse and hospitalization events common within a year.
DOI: 10.1182/blood-2025-4459 -
Autoimmune Hemolytic Anemia in Pregnancy
A case report describing a pregnant woman with warm autoimmune hemolytic anemia due to a warm autoantibody with an underlying alloantibody (anti-E), detailing diagnostic workup, transfusion strategies with antigen-matched units and steroids, and favorable maternal–fetal outcomes.
DOI: 10.1309/lmxjo5ty9no1 -
Warm Autoimmune Hemolytic Anemia
This paper provides a comprehensive overview of Warm Autoimmune Hemolytic Anemia (AIHA), detailing its classification, clinical presentation, diagnostic criteria, underlying mechanisms, associated conditions, and treatment options.
DOI: 10.1016/j.hoc.2015.01.001 -
Therapeutic plasma exchange in refractory warm autoimmune hemolytic anemia
This study reports on a case of a 59-year-old man with refractory warm autoimmune hemolytic anemia who underwent therapeutic plasma exchange, highlighting the challenges and outcomes associated with the procedure.
DOI: 10.1111/trf.13932 -
A randomized and double‐blind controlled trial evaluating the safety and efficacy of rituximab for warm auto‐immune hemolytic anemia in adults (the RAIHA study)
This phase 3 multicenter randomized double-blind placebo-controlled trial demonstrated that rituximab combined with prednisone significantly improves the overall response rate in adults with newly diagnosed warm autoimmune hemolytic anemia compared to placebo.
DOI: 10.1002/ajh.24570 -
Venous thromboembolism related to warm autoimmune hemolytic anemia: A case–control study
This study investigates the frequency, presentation, and risk factors for venous thromboembolism (VTE) in patients with warm autoimmune hemolytic anemia (wAIHA), finding that 20% of patients experienced VTE, primarily during severe hemolytic flares, and emphasizes the need for V…
DOI: 10.1016/j.autrev.2015.07.001 -
Hypereosinophilic Syndrome with Eosinophilic Myocarditis and Coexisting Autoimmune Hemolytic Anemia: A Case Report
63-year-old Japanese woman with idiopathic hypereosinophilic syndrome presenting eosinophilic myocarditis and coexisting warm autoimmune hemolytic anemia, rapidly improving with prednisolone and warfarin and showing resolution of left ventricular apical thrombus and normalizatio…
DOI: 10.2169/internalmedicine.6915-25 -
Flow cytometric determination of RBC survival in autoimmune hemolytic anemia
This study presents a flow cytometric technique for determining the survival of transfused and autologous red blood cells (RBCs) in a patient with warm autoimmune hemolytic anemia (WAIHA), highlighting the method's advantages over traditional radioactive labeling.
DOI: 10.1046/j.1537-2995.2001.41040493.x -
Autoimmune haemolytic anaemia in childhood associated with non‐complement binding IgM autoantibodies
Non-complement-binding IgM autoantibodies bound to circulating red blood cells can cause warm autoimmune hemolytic anemia in children, often with DAT negativity, indicating a complement-independent mechanism of RBC destruction.
DOI: meta/10.1111/j.1365-2141.1987.tb06137.x -
Autoimmune hemolytic anemia associated with renal urothelial cancer: A case report and literature review
This case report describes a 52-year-old man with warm autoimmune hemolytic anemia (AIHA) associated with renal urothelial cancer who achieved temporary hematologic improvement after nephroureterectomy, highlighting a rare paraneoplastic presentation and its clinical management.
DOI: 10.1186/s12894-015-0071-0 -
Impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity
This study investigates the impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity, revealing that mutations in epitope regions can significantly impair the effectiveness of vaccine-induced CD4+ T-cell responses.
DOI: 10.1038/s41541-025-01088-y -
Vaccine-induced thrombotic thrombocytopenia (VITT): first report from India
This study reports the first cases of vaccine-induced thrombotic thrombocytopenia (VITT) in India, detailing the clinical presentations, management, and outcomes of two young male patients following ChAdOx1 nCoV-19 vaccination.
DOI: 10.1186/s12959-022-00370-6 -
Addition of N-glycosylation sites on the globular head of the H5 hemagglutinin induces the escape of highly pathogenic avian influenza A H5N1 viruses from vaccine-induced immunity
This study investigates how the addition of N-glycosylation sites on the hemagglutinin of H5N1 avian influenza viruses can induce escape from vaccine-induced immunity, demonstrating that a single additional glycosite significantly contributes to this immune evasion.
DOI: 10.1016/j.virol.2015.08.033 -
Impact of p53-based immunization on primary chemically-induced tumors
In a mouse model of chemically induced primary tumors, p53-based DNA and dendritic cell vaccines induce WT-p53–specific CTLs but drive immunoselection, leading to epitope loss and MHC downregulation in outgrowing tumors and only modest protection against carcinogenesis.
DOI: 10.1002/ijc.20686 -
Determinants of COVID-19 vaccine-induced myocarditis
A VAERS-based analysis describing the characteristics and determinants of COVID-19 vaccine–induced myocarditis, highlighting a higher risk in young males after dose 2 and a temporal clustering of events following vaccination.
DOI: 10.1177/20420986241226566 -
HPV 18 antibody levels, clinical efficacy and induced immune memory: A trio?
This study examines the long-term seroconversion rates and immune memory associated with HPV vaccination, highlighting the potential limitations in understanding vaccine-induced protection due to insufficient follow-up time and the complexities of natural immunity.
DOI: 10.1016/j.vaccine.2009.07.009 -
An influenza A/H3 outbreak during the 2004/2005 winter in elderly vaccinated people living in a nursing home
This study investigates the immune response and effectiveness of the 2004/2005 influenza vaccine in preventing an outbreak of the A/H3N2 drift variant among elderly residents in a nursing home, revealing that while vaccination induced adequate antibody responses, it failed to pr…
DOI: 10.1016/j.vaccine.2006.05.037 -
Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients
This study investigates the impact of the route of administration (intradermal vs. intranodal) on the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients, revealing that intradermal vaccination is more effective in eliciting functio…
DOI: 10.1158/1078-0432.CCR-11-1261 -
Comparative immunogenicity of live influenza viruses and their solubilized neuraminidases: Results of mouse protection experiments
This study investigates the immunogenicity and protective efficacy of live influenza virus strains and their solubilized neuraminidases in mice, demonstrating that live virus vaccination induces stronger immunity compared to subunit vaccines.
DOI: 10.1007/BF01315002 -
Seasonal Maintenance of Influenza Vaccine-Induced Antibody Response in Kidney Transplant Recipients
This study investigates the maintenance of influenza vaccine-induced antibody responses in kidney transplant recipients compared to healthy controls, finding that while both groups can maintain protective antibody levels, transplant recipients show a significantly lower response…
DOI: 10.1159/000341653 -
Evaluation of a novel vaccine candidate derived from newly excysted juveniles of Fasciola hepatica in sheep
This study evaluates the immune response and protective efficacy of a novel vaccine candidate composed of four antigens derived from newly excysted juveniles of Fasciola hepatica in sheep, revealing that while the vaccine induced a strong IgG1 response, it did not significantly …
DOI: 10.1038/s41598-025-00109-z